Unconventional T Cell Targets for Cancer Immunotherapy

Dale I Godfrey; Jérôme Le Nours; Daniel M Andrews; Adam P Uldrich; Jamie Rossjohn

doi:10.1016/j.immuni.2018.03.009

Unconventional T Cell Targets for Cancer Immunotherapy

Immunity. 2018 Mar 20;48(3):453-473. doi: 10.1016/j.immuni.2018.03.009.

Authors

Dale I Godfrey¹, Jérôme Le Nours², Daniel M Andrews³, Adam P Uldrich⁴, Jamie Rossjohn⁵

Affiliations

¹ Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria 3010, Australia; ARC Centre of Excellence in Advanced Molecular Imaging, University of Melbourne, Parkville, Victoria 3010, Australia. Electronic address: godfrey@unimelb.edu.au.
² Infection and Immunity Program and The Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia; ARC Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, Victoria 3800, Australia.
³ Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, Victoria, Australia.
⁴ Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria 3010, Australia; ARC Centre of Excellence in Advanced Molecular Imaging, University of Melbourne, Parkville, Victoria 3010, Australia.
⁵ Infection and Immunity Program and The Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia; ARC Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, Victoria 3800, Australia; Institute of Infection and Immunity, Cardiff University, School of Medicine, Heath Park, Cardiff CF14 4XN, UK. Electronic address: jamie.rossjohn@monash.edu.

PMID: 29562195
DOI: 10.1016/j.immuni.2018.03.009

Abstract

Most studies on the immunotherapeutic potential of T cells have focused on CD8 and CD4 T cells that recognize peptide antigens (Ag) presented by polymorphic major histocompatibility complex (MHC) class I and MHC class II molecules, respectively. However, unconventional T cells, which interact with MHC class Ib and MHC-I like molecules, are also implicated in tumor immunity, although their role therein is unclear. These include unconventional T cells targeting MHC class Ib molecules such as HLA-E and its murine ortholog Qa-1b, natural killer T (NKT) cells, mucosal associated invariant T (MAIT) cells, and γδ T cells. Here, we review the current understanding of the roles of these unconventional T cells in tumor immunity and discuss why further studies into the immunotherapeutic potential of these cells is warranted.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Biomarkers
Clinical Studies as Topic
Combined Modality Therapy
Gene Expression Regulation, Neoplastic / drug effects
Histocompatibility Antigens / immunology
Histocompatibility Antigens / metabolism
Humans
Immunomodulation / drug effects
Immunotherapy*
Molecular Targeted Therapy*
Neoplasms / immunology*
Neoplasms / metabolism
Neoplasms / therapy*
Signal Transduction / drug effects
T-Lymphocyte Subsets / drug effects
T-Lymphocyte Subsets / immunology
T-Lymphocyte Subsets / metabolism
T-Lymphocytes / drug effects
T-Lymphocytes / immunology*
T-Lymphocytes / metabolism*
Treatment Outcome

Substances

Biomarkers
Histocompatibility Antigens